Deep inside every cell, a family of enzymes decides which proteins survive and which are marked for destruction. These E3 ligases govern almost every biological process, yet for nearly two decades scientists could not even agree on how many of them exist. A 2026 atlas has now delivered the field's first authoritative census.
The Cell's Gatekeepers
E3 ligases attach a small tag called ubiquitin to target proteins, flagging them for recycling or altering their activity. This tagging system controls the cell's balance of proteins and touches processes ranging from cell division to immune signaling. Because they are so central, malfunctioning E3 ligases are implicated in cancer and neurodegenerative disease.
Ending the Head-Count Dispute
Despite their importance, published estimates of how many E3 ligases the human genome encodes varied widely, and different databases listed conflicting sets. Led by researchers at WEHI, the new work built a curated, gold-standard reference by systematically evaluating candidate genes, resolving disagreements that had lingered since the field's early days.
- Identifies 672 high-confidence human E3 ligases.
- Flags additional candidate enzymes and previously unknown domains.
- Finds that 26% of E3 genes carry disease-associated variants.
- Provides a shared reference to standardize future research.
Why a Reliable Atlas Matters
Drug developers are increasingly interested in E3 ligases because of targeted protein degradation, an approach that hijacks these enzymes to destroy disease-causing proteins that were once considered undruggable. A trustworthy, complete list of the enzymes is essential groundwork for choosing which ones to target and understanding their normal roles.
Links to Disease
The atlas found that more than a quarter of E3 ligase genes harbor variants linked to conditions including cancer and neurodegeneration. Mapping these connections gives researchers a prioritized set of enzymes to investigate as potential drivers of disease or as therapeutic entry points.
A Foundation for the Field
Beyond the raw count, the atlas describes the structural domains and features of these enzymes, offering clues about how each recognizes its protein targets. Standardizing this information means laboratories worldwide can build on a common foundation rather than reconciling mismatched datasets.
The authors frame the resource as a reference tool rather than a final word, expecting refinements as experimental methods improve. Even so, transforming a long-running disagreement into a curated, high-confidence catalog is a substantial step, giving both basic biologists and drug hunters firmer ground on which to work.